The big medical news of 2026 is about the big blockbuster drug of 2025. Semaglutide (a.k.a. Ozempic, a.k.a. Wegovy) is now off patent in Canada. In the U.S. and the rest of the world, patent ...

Having generics that might significantly reduce the price is welcome, obesity physician says. Health Canada says it is reviewing nine submissions (new window) for generic versions of popular weight ...

Drug companies in Canada are allowed to make lower priced generic versions of the blockbuster drug Ozempic as of next week, but experts say patients shouldn’t expect it to be available for at least a ...

In 2026, Novo Nordisk’s patent on semaglutide will expire in several countries, including India and China. Generic-drug makers are poised to flood these markets with inexpensive products. Industry ...

The U.S. Food and Drug Administration announced Wednesday that it will relax certain rules for approving low-cost versions of some high-priced medications, in an effort to speed up access to cheaper ...

FRANKFURT (Reuters) -Novartis' blockbuster heart treatment Entresto saw sales growth stall in the third quarter of the year, dragging the Swiss company's shares lower, as its top-selling drug comes ...

Jamie Dimon is right to be alarmed about our national-security vulnerabilities, especially an overreliance on China and India for generic prescription drugs (“Investments for National Security,” op-ed ...

Prescription drugs aren't optional, but the cost often feels like it is stacked against you. Whether you take daily medications for blood pressure, cholesterol, or thyroid health, the bills can add up ...

German generics maker Stada has settled on a buyout by CapVest Partners, putting an end to its previously reported IPO ambitions. The CapVest deal changes Stada’s ownership from private equity firms ...

Medications are rarely made from start to finish in a single country; raw materials, active ingredients and final products often cross multiple borders before reaching patients in the U.S., The New ...